Skip to main content
AARD
NASDAQ Life Sciences

阿德瓦克治疗公司报告第四季度/2025财年结果，并在第三阶段试验暂停后提供商业更新

feedReported by Reuters
Sentiment info
Neutral
Importance info
8
Price
$4.14
Mkt Cap
$88.508M
52W Low
$4.01
52W High
$17.94
Market data snapshot near publication time

summarizeSummary

阿德瓦克治疗公司已经报告了其第四季度和2025财年的财务结果，并提供了商业更新。这一声明是在公司披露其第三阶段HERO和OLE试验由于意外的安全信号而暂停招募和给药后不久发布的。对于一家小盘生物技术公司来说，这些财务结果至关重要，提供了对公司在重大临床挫折后现金储备和运营可持续性的洞察。交易者将密切审查财务状况以及商业更新中有关试验暂停的影响和公司管道前进道路的任何进一步细节。

在该公告发布时，AARD的交易价格为$4.14，交易所为NASDAQ，所属行业为Life Sciences，市值约为$8850.8万。 52周交易区间为$4.01至$17.94。 这则新闻被评估为中性市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed AARD - Latest Insights

AARD
Apr 03, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Aardvark Therapeutics Activates $150M At-The-Market Offering, Signaling Massive Potential Dilution Amidst Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 6:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Establishes $150M ATM Program Amidst Trial Pause, Signaling Significant Dilution
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
9
Aardvark Therapeutics Files $400M Universal Shelf, Including $150M ATM Offering, Amidst Phase 3 Trial Pause
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Aardvark Therapeutics Reports Q4/FY25 Results, Provides Business Updates Following Phase 3 Trial Pause
Sentiment: Neutral
View Wiseek Article
AARD
Mar 23, 2026, 4:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Aardvark Therapeutics Halts All Lead Clinical Trials Due to Cardiac Safety Concerns, Delays Key Data
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Aardvark Pauses Phase 3 Trials for ARD-101 Due to Cardiac Safety Concerns; Provides Q4/FY25 Financials
Sentiment: Negative
View Wiseek Article
AARD
Mar 23, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Aardvark Therapeutics Pauses Lead Phase 3 Drug Trial Over Cardiac Safety Signals
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:27 PM EST
Filing Type: 8-K
Importance Score:
9
Aardvark Therapeutics Pauses Key Phase 3 Trial for ARD-101 Due to Cardiac Safety Observations
Sentiment: Negative
View Wiseek Article
AARD
Feb 27, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
9
Cardiac Safety Concerns Halt Aardvark's Phase 3 Prader-Willi Trial
Sentiment: Negative
View Wiseek Article
AARD
Feb 12, 2026, 8:17 AM EST
Filing Type: 8-K
Importance Score:
8
Aardvark Therapeutics Establishes Dermatology Subsidiary, Appoints CEO, and Expands Executive Team
Sentiment: Positive
View Wiseek Article